Robert Orlowski, MD, PhD, professor of Medicine at The University of Texas MD Anderson Cancer Center, discusses prophylactic ...
Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression and treatment-free following a single ...
Triple-class exposed patients with three prior lines of therapy in CARTITUDE-1 and CARTITUDE-4 achieved a median PFS of 50.4 months after a ...
Coherus Oncology, Inc. (NASDAQ: CHRS) today announced compelling six-year overall survival (OS) follow-up results from the Phase 3 JUPITER-02 trial evaluating LOQTORZI® (toripalimab-tpzi) plus ...
Moderna has decided to halt the development of its mRNA-1647 vaccine for congenital cytomegalovirus (CMV) infections – once touted as a future blockbuster – after it failed the Phase 3 CMVictory trial ...
According to the Pan American Health Organization, 7 out of 10 deaths in people over 70 are from non-communicable diseases (NCDs). Aging itself is the single greatest risk factor for the majority of ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
A 55-year-old white man with a medical history of well-controlled type 2 diabetes, rheumatoid arthritis and fibromyalgia ...
Food intolerances, food sensitivities, and food allergies can all produce negative symptoms, ranging from undesirable to downright dangerous. Food intolerances can produce uncomfortable or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback